142 related articles for article (PubMed ID: 10847472)
1. Low doses interferon-alpha in the treatment of high-risk cutaneous melanoma. Melanoma Cooperative Group.
Ascierto PA; Palmieri G; Strazzullo M; Daponte A; Botti G; Satriano SM; Motti ML; Mozzillo N
Ann Oncol; 2000 Apr; 11(4):487-90. PubMed ID: 10847472
[No Abstract] [Full Text] [Related]
2. Adjuvant use of interferon alpha 2b is not justified in patients with stage IIb/III melanoma.
Bajetta E
Nat Clin Pract Oncol; 2008 Jan; 5(1):4-5. PubMed ID: 18043604
[No Abstract] [Full Text] [Related]
3. Review of sentinel lymph node biopsy and systemic interferon for melanoma: promising but investigational modalities.
Otley CC; Zitelli JA
Dermatol Surg; 2000 Mar; 26(3):177-80. PubMed ID: 10759789
[TBL] [Abstract][Full Text] [Related]
4. Node positive melanoma--a positive note?
Kelly J; Kerin MJ
Surgeon; 2012 Apr; 10(2):63-4. PubMed ID: 22385525
[No Abstract] [Full Text] [Related]
5. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma.
Grob JJ; Dreno B; de la Salmonière P; Delaunay M; Cupissol D; Guillot B; Souteyrand P; Sassolas B; Cesarini JP; Lionnet S; Lok C; Chastang C; Bonerandi JJ
Lancet; 1998 Jun; 351(9120):1905-10. PubMed ID: 9654256
[TBL] [Abstract][Full Text] [Related]
6. Management of cutaneous melanoma.
Tsao H; Atkins MB; Sober AJ
N Engl J Med; 2004 Sep; 351(10):998-1012. PubMed ID: 15342808
[No Abstract] [Full Text] [Related]
7. Adjuvant interferon therapy for melanoma.
Hancock B; Wheatley K; Ives N; Gore M
J Clin Oncol; 2005 Apr; 23(10):2431; author reply 2431-2. PubMed ID: 15800339
[No Abstract] [Full Text] [Related]
8. Topical imiquimod in the treatment of metastatic melanoma to skin.
Wolf IH; Smolle J; Binder B; Cerroni L; Richtig E; Kerl H
Arch Dermatol; 2003 Mar; 139(3):273-6. PubMed ID: 12622616
[No Abstract] [Full Text] [Related]
9. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial.
Eggermont AM; Suciu S; MacKie R; Ruka W; Testori A; Kruit W; Punt CJ; Delauney M; Sales F; Groenewegen G; Ruiter DJ; Jagiello I; Stoitchkov K; Keilholz U; Lienard D;
Lancet; 2005 Oct; 366(9492):1189-96. PubMed ID: 16198768
[TBL] [Abstract][Full Text] [Related]
10. Prospective randomized trial of interferon alfa-2b and interleukin-2 as adjuvant treatment for resected intermediate- and high-risk primary melanoma without clinically detectable node metastasis.
Hauschild A; Weichenthal M; Balda BR; Becker JC; Wolff HH; Tilgen W; Schulte KW; Ring J; Schadendorf D; Lischner S; Burg G; Dummer R
J Clin Oncol; 2003 Aug; 21(15):2883-8. PubMed ID: 12885805
[TBL] [Abstract][Full Text] [Related]
11. Meyerson's phenomenon in a patient affected by high-risk melanoma under treatment with interferon-α.
Zonta E; Chiarion V; Zarian H; Peserico A; Alaibac M
Melanoma Res; 2012 Jun; 22(3):284-5. PubMed ID: 22543678
[No Abstract] [Full Text] [Related]
12. High-dose adjuvant interferon therapy for melanoma.
Licata AG
Dermatol Nurs; 1998 Oct; 10(5):334-6. PubMed ID: 9873271
[TBL] [Abstract][Full Text] [Related]
13. [To outwit melanoma with its own tricks].
Bischoff A
MMW Fortschr Med; 2003 Apr; 145(15):4-6, 8, 10. PubMed ID: 15104255
[No Abstract] [Full Text] [Related]
14. Adjuvant interferon therapy for melanoma: high-dose, low-dose, no dose, which dose?
Schuchter LM
J Clin Oncol; 2004 Jan; 22(1):7-10. PubMed ID: 14665612
[No Abstract] [Full Text] [Related]
15. How does interferon work? Does it even matter?
Sondak VK
Cancer; 2002 Sep; 95(5):947-9. PubMed ID: 12209676
[No Abstract] [Full Text] [Related]
16. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.
Hancock BW; Wheatley K; Harris S; Ives N; Harrison G; Horsman JM; Middleton MR; Thatcher N; Lorigan PC; Marsden JR; Burrows L; Gore M
J Clin Oncol; 2004 Jan; 22(1):53-61. PubMed ID: 14665609
[TBL] [Abstract][Full Text] [Related]
17. The role of adjuvant interferon in high risk melanoma patients.
Dermatol Surg; 2000 Jun; 26(6):607-8. PubMed ID: 10848951
[No Abstract] [Full Text] [Related]
18. Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macrometastatic nodes: an open-label, randomised, phase 3 European Association for Dermato-Oncology (EADO) study.
Grob JJ; Jouary T; Dréno B; Asselineau J; Gutzmer R; Hauschild A; Leccia MT; Landthaler M; Garbe C; Sassolas B; Herbst RA; Guillot B; Chene G; Pehamberger H
Eur J Cancer; 2013 Jan; 49(1):166-74. PubMed ID: 22975216
[TBL] [Abstract][Full Text] [Related]
19. [Interferons and malignant melanoma].
Dreno B
Rev Med Interne; 2002 Nov; 23 Suppl 4():489s-493s. PubMed ID: 12481404
[TBL] [Abstract][Full Text] [Related]
20. Current therapy of cutaneous melanoma.
Mays SR; Nelson BR
Cutis; 1999 May; 63(5):293-8. PubMed ID: 10349545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]